Treatment of severe eosinophilic asthma with anti-interleukin-5 monoclonal antibody in Motol University Hospital between 2017 and 2019
2019
Abstract
The experience of therapy with monoclonal antibody to IL-5 in severe Th2 astma proves, that it is effective and safe. It leads to disease control with reducing/termination of systemic corticotherapy, improving lung function and after that improving the quality of life.